Case Report

Bell´s Palsy After Astra Zenica COVID-19 Vaccination

Volume: 7 Number: 4 December 30, 2022
EN

Bell´s Palsy After Astra Zenica COVID-19 Vaccination

Abstract

We present a case of peripheral facial palsy developing after the first dose of AZD1222, Astra Zeneca`s COVID-19 vaccine. A 31- year-old female received her first dose of AZD1222 vaccine against COVID-19. Later the same day, she developed swelling around her neck and head. The next day, she woke up with hanging eyelid, hanging mouth and loss of sensibility on the left side of her face- indications of peripheral facial paralysis. She later on developed hyperesthesia on the upper extremities. Before vaccination, the patient was healthy and had no history of neurological disease. She fully recovered from the paresis after 2-3 days. Five months after she received her first and only dose of the vaccine, she still complains of severe hyperesthesia in her upper extremities. There have been several international case reports of Bell´s palsy after COVID-19- vaccination, but Bell´s palsy is not yet a confirmed adverse effect of any COVID-19 vaccine. The aim of this case report is to raise awareness about Bell´s palsy as a possible adverse effect of Astra Zeneca´s COVID-19 vaccine.

Keywords

References

  1. Colella, G., Orlandi, M. & Cirillo, N. Bell’s palsy following COVID-19 vaccination. J Neurol 268, 3589–3591 (2021). https://doi.org/10.1007/s00415-021-10462-4
  2. Tomey R. Man develops Bell´s palsy after getting Pfizer/BioNtech vaccine. Pharmaceutical Fraud. [oppdatert:21.07.21; hentet:20.07.21] https://pharmaceuticalfraud.com/2021-07-21-man-develops-bells-palsy-after-pfizer-vaccination.html
  3. Mutsch M., Zhou W., Rhodes P., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell´s palsy in Switzerland. N Engl J Med 2004; 350:896-903 DOI: 10.1056/NEJMoa030595
  4. WHO. Covid-19 advice for the public: Getting vaccinated. Organization for world health; [oppdatert:14.07.21; hentet:28.07.21] https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice

Details

Primary Language

English

Subjects

​Internal Diseases

Journal Section

Case Report

Authors

Publication Date

December 30, 2022

Submission Date

March 16, 2022

Acceptance Date

December 30, 2022

Published in Issue

Year 2022 Volume: 7 Number: 4

APA
Albanna, R. (2022). Bell´s Palsy After Astra Zenica COVID-19 Vaccination. Journal of Immunology and Clinical Microbiology, 7(4), 88-91. https://doi.org/10.58854/jicm.1089137
AMA
1.Albanna R. Bell´s Palsy After Astra Zenica COVID-19 Vaccination. J Immunol Clin Microbiol. 2022;7(4):88-91. doi:10.58854/jicm.1089137
Chicago
Albanna, Rozan. 2022. “Bell´s Palsy After Astra Zenica COVID-19 Vaccination”. Journal of Immunology and Clinical Microbiology 7 (4): 88-91. https://doi.org/10.58854/jicm.1089137.
EndNote
Albanna R (December 1, 2022) Bell´s Palsy After Astra Zenica COVID-19 Vaccination. Journal of Immunology and Clinical Microbiology 7 4 88–91.
IEEE
[1]R. Albanna, “Bell´s Palsy After Astra Zenica COVID-19 Vaccination”, J Immunol Clin Microbiol, vol. 7, no. 4, pp. 88–91, Dec. 2022, doi: 10.58854/jicm.1089137.
ISNAD
Albanna, Rozan. “Bell´s Palsy After Astra Zenica COVID-19 Vaccination”. Journal of Immunology and Clinical Microbiology 7/4 (December 1, 2022): 88-91. https://doi.org/10.58854/jicm.1089137.
JAMA
1.Albanna R. Bell´s Palsy After Astra Zenica COVID-19 Vaccination. J Immunol Clin Microbiol. 2022;7:88–91.
MLA
Albanna, Rozan. “Bell´s Palsy After Astra Zenica COVID-19 Vaccination”. Journal of Immunology and Clinical Microbiology, vol. 7, no. 4, Dec. 2022, pp. 88-91, doi:10.58854/jicm.1089137.
Vancouver
1.Rozan Albanna. Bell´s Palsy After Astra Zenica COVID-19 Vaccination. J Immunol Clin Microbiol. 2022 Dec. 1;7(4):88-91. doi:10.58854/jicm.1089137

88x31.png 

Creative Commons Attribution Non-Commercial License: The articles in the Journal of Immunology and Clinical Microbiology are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

JICM is a product of QMEL® medicine & publishing